Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study

Conclusion Tolerance-based capecitabine dose escalation did not lead to more toxicity in DPYD variant carriers compared with wild-type patients. Our results can guide future prospective research.
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: CLINICAL REPORTS Source Type: research